spacer
home > epc > spring 2019 > future-proofing the supply chain
PUBLICATIONS
European Pharmaceutical Contractor

Future-Proofing the Supply Chain

With the regulatory landscape between countries continuing to change and the uncertainty surrounding the changes that Brexit will bring to clinical trial regulations across Europe, it is becoming increasingly important to prepare for changes that might hit the clinical trial supply chain.

With the recent expansion of the clinical trial industry as a result of growing drug innovation and targeted therapies, efforts to tackle ineffectiveness and safety concerns are high on the agenda. From changing import and export regulations to temperature deviation, many challenges will affect the clinical trial supply chain. Planning for these uncertainties, especially in light of prevalent disruptive technologies, now requires more attention than ever.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Simon Jones is the Vice President of Global Products for PRISYM ID, responsible for managing the end-to-end lifecycle of the company product portfolio. He has 20 years of experience in delivering product strategies and product positioning which address market opportunities effectively. Simon is a subject expert in clinical trials labelling, researching this market and discussing industry challenges with PRISYM ID customers and keeping them up-to-date on market trends, regulatory changes, and technology alternatives.
spacer
Simon Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement